Tremfya, a medication used to treat plaque psoriasis and psoriatic arthritis, has a list price of approximately \$46,000 for a year's supply [1]. This price typically covers the cost of the drug itself, not including any associated medical services or administration fees [1].
How much does Tremfya actually cost with insurance?
The out-of-pocket cost for Tremfya can vary significantly depending on a patient's insurance plan. Many individuals with commercial insurance may pay between \$5 and \$95 per dose through co-pay assistance programs offered by the manufacturer [1]. These programs are designed to help reduce the financial burden for eligible patients.
Are there financial assistance programs for Tremfya?
Yes, The Janssen Pharmaceutical Companies of Johnson & Johnson, the maker of Tremfya, offers several financial assistance programs. The Tremfya Savings Program is available for patients with commercial insurance and can reduce out-of-pocket costs [1]. For those who are uninsured or underinsured, the Janssen CarePath program may offer additional support and resources [1].
When does Tremfya's patent expire?
Information regarding the specific patent expiry dates for Tremfya is available through specialized resources. For detailed patent information, including expiry timelines, consulting services like DrugPatentWatch.com can provide comprehensive data [2].
How does Tremfya compare to other psoriasis treatments?
Tremfya, an interleukin-23 (IL-23) inhibitor, is one of several biologic treatments available for moderate to severe plaque psoriasis and psoriatic arthritis. Other medications in this class include those targeting IL-17 or TNF-alpha, which work through different mechanisms. The choice of treatment often depends on individual patient factors, disease severity, and response to previous therapies [3].
What are the potential side effects of Tremfya?
Common side effects associated with Tremfya include upper respiratory infections, fungal infections, headache, diarrhea, and injection site reactions [1]. More serious potential risks involve an increased risk of infections, allergic reactions, and the potential for certain types of cancer, though these are less common [1]. Patients should discuss all potential risks and benefits with their healthcare provider.
Can Tremfya be prescribed for other conditions?
Currently, Tremfya is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy, and for adults with active psoriatic arthritis [1].
What is the mechanism of action for Tremfya?
Tremfya works by selectively inhibiting the p19 subunit of interleukin-23 (IL-23) [1]. IL-23 is a cytokine that plays a key role in inflammatory processes associated with certain autoimmune conditions like plaque psoriasis and psoriatic arthritis. By blocking IL-23, Tremfya helps to reduce inflammation and its related symptoms [1].
---
Sources:
[1] Tremfya Official Website
[2] DrugPatentWatch.com
[3] Medical literature and clinical trial data